Detecting sepsis
AssigneeMologic Limited
InventorsPaul Davis, Gita Parekh, Chris Dunston
Life of this patent
Estimating the term…
Abstract
A method for predicting sepsis or diagnosing systemic inflammatory response syndrome (SIRS) and/or sepsis in a subject comprises determining levels of at least three markers selected from CCL23, A1AT, CRP, sICAM, PLA2, IL-6, procalcitonin, MMP8, TNFalpha, AcPGP, enzymatic MMP activity, TIMP1, sRAGE and desmosine in a sample taken from the subject. The combined levels of the at least three markers are used to predict or diagnose SIRS and/or sepsis. The methods may be performed on a subject with SIRS and which is used to identify an infection in the subject. A preferred panel of markers includes CCL23, A1AT, sICAM, sICAM/VCAM-1 and CRP. Corresponding products, methods of treatment and medical uses are provided.
Claims24
-49. (canceled)
A method for predicting sepsis or diagnosing systemic inflammatory response syndrome (SIRS) and/or sepsis in a subject, the method comprising determining levels of at least three markers selected from CCL23, A1AT, CRP, sICAM, PLA2, IL-6, procalcitonin, MMP8, TNFalpha, AcPGP, enzymatic MMP activity, TIMP1, sRAGE and desmosine in a sample taken from the subject, wherein the combined levels of the at least three markers are used to predict or diagnose SIRS and/or sepsis.
A method for monitoring a subject at risk of developing sepsis, the method comprising determining levels of at least three markers in samples taken from the subject at multiple time points, wherein the monitored levels of the at least three markers are used to predict or diagnose SIRS and/or sepsis.
A method of treating sepsis comprising administering an antibiotic to the subject suffering from sepsis, wherein the subject displays, in a sample, an altered level of at least three markers selected from CCL23, A1AT, CRP, sICAM, PLA2, IL-6, procalcitonin, MMP8, TNFalpha, AcPGP, enzymatic MMP activity, TIMP1, sRAGE and desmosine.
A system or test kit for predicting or diagnosing systemic inflammatory response syndrome (SIRS) and/or sepsis in a subject, comprising:
- a) One or more testing devices for determining levels of at least three markers selected from CCL23, A1AT, CRP, sICAM, PLA2, IL-6, procalcitonin, MMP8, TNFalpha, AcPGP, enzymatic MMP activity, TIMP1, sRAGE and desmosine in a sample
- b) A processor;
- and
- c) A storage medium comprising a computer application that, when executed by the processor, is configured to:
- i) Access and/or calculate the determined levels of each marker in the sample on the one or more testing devices
- ii) Calculate a test score from the levels of the markers in the sample that predicts or diagnoses SIRS and/or sepsis;
- and
- iii) Output from the processor the predicted or diagnostic result for the subject.
A testing device, testing kit or testing composition of matter comprising:
- a) A sample receiving zone to which a sample from a subject is added;
- b) A conjugate zone comprising at least three labelled binding reagents, each of which specifically binds to one of the at least three markers selected from CCL23, A1AT, CRP, sICAM, PLA2, IL-6, procalcitonin, MMP8, TNFalpha, AcPGP, enzymatic MMP activity, TIMP1, sRAGE and desmosine;
- and
- c) A solid support defining a liquid flow path for the sample and comprising corresponding test lines for each of the at least three markers, each test line comprising an immobilised further binding reagent that also specifically binds to one of the at least three markers thereby immobilising the marker at the test line to produce a signal via the labelled binding reagent also specifically bound to the marker.
Dependencies are inferred from the claim text.